Table 2.
Data Collection Measures and Instruments
Measure | Data Collected | Method |
---|---|---|
Primary Outcome | Hemoglobin A1c | Blood specimens will be obtained at baseline, 3-, and 6-months visits. |
Secondary Outcomes | Blood Pressure | Blood pressure readings will be obtained at baseline, 3-, and 6-months visits. |
Quality of life | Quality of life will be measured by the SF-12 [31], which is a valid and reliable instrument to measure functional status. | |
Process Measures | Information | This will be measured by the 24-item Diabetes Knowledge Questionnaire (DKQ) [32] |
Motivation | This will be measured with the 12-item Diabetes Fatalism Scales (DFS) [33]. | |
Self-Efficacy | This will be measured by the perceived diabetes self-management scale (PDSMS) [34]. | |
Behavioral Skills | This will be assessed with the Summary of Diabetes Self-Care Activities (SDSCA) scale [35]. | |
Medication Adherence | This will be measured with the new 8-item self-report Morisky Medication Adherence Scale (MMAS) [36]. | |
Self-report measures | Demographics | Previously validated items from the 2002 National Health Interview Survey [37] will be used to capture age, gender, race/ethnicity, marital status, household income, and health insurance. |
Social support | The Medical Outcomes Study (MOS) Social Support Survey [38] will be used to measure social support. | |
Health Literacy | The abbreviated version of the Test of Functional Health Literacy in Adults (S-TOFHLA) [39] is designed to rapidly screen patients for potential health literacy problems. | |
Depression | The PHQ-9 is a brief questionnaire that scores each of the 9 DSM-IV criteria for depression [40]. | |
Medical Comorbidity | The patient's history of medical comorbidity will be documented using a standardized and validated questionnaire [41]. | |
Service Delivery Perceptions | This will be assessed with 5 items that have been previously validated in mental health studies. The items were slightly modified to be relevant to diabetes. | |
Treatment Credibility | To assess for differences in outcome expectancy, a modified treatment credibility scale developed by Borkovec and Nau (1972) will be used [42]. | |
Resource Utilization & Cost | The perspective of cost will be that of the payer. Previously validated questions on resource utilization will be administered as a part of the baseline, 3-, and 6-month visits. |